Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)

Background Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer’s disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plast...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Current controlled trials in cardiovascular medicine Ročník 20; číslo 1; s. 191 - 10
Hlavní autori:	Femminella, Grazia Daniela, Frangou, Eleni, Love, Sharon B., Busza, Gail, Holmes, Clive, Ritchie, Craig, Lawrence, Robert, McFarlane, Brady, Tadros, George, Ridha, Basil H., Bannister, Carol, Walker, Zuzana, Archer, Hilary, Coulthard, Elizabeth, Underwood, Ben R., Prasanna, Aparna, Koranteng, Paul, Karim, Salman, Junaid, Kehinde, McGuinness, Bernadette, Nilforooshan, Ramin, Macharouthu, Ajay, Donaldson, Andrew, Thacker, Simon, Russell, Gregor, Malik, Naghma, Mate, Vandana, Knight, Lucy, Kshemendran, Sajeev, Harrison, John, Brooks, David J., Passmore, Anthony Peter, Ballard, Clive, Edison, Paul
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BioMed Central 03.04.2019 BioMed Central Ltd Springer Nature B.V BMC
Predmet:	Activities of Daily Living Alzheimer Disease - drug therapy Alzheimer Disease - metabolism Alzheimer Disease - physiopathology Alzheimer Disease - psychology Alzheimer's disease Antidiabetics Apoptosis Batteries Biomarkers Biomedicine Brain Brain - drug effects Brain - metabolism Brain - physiopathology Brain research Care and treatment Cell growth Cerebral glucose metabolic rate Clinical trials Clinical Trials, Phase II as Topic Cognition & reasoning Cognition - drug effects Dementia Development and progression Diabetes Double-Blind Method Drug dosages Genetic engineering Glucagon Glucagon-Like Peptide-1 Receptor - metabolism Glucagon-Like Peptide-1 Receptor Agonists Glucose Glucose - metabolism Growth factors Health Sciences Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Insulin Liraglutide Liraglutide - adverse effects Liraglutide - therapeutic use Medical research Medicine Medicine & Public Health Memory Memory - drug effects Metabolism Morbidity Multicenter Studies as Topic Neurons Neuroprotective Agents - adverse effects Neuroprotective Agents - therapeutic use Obesity Oligomers Peptides Phosphorylation Physiology Proteins Randomised controlled trial Randomized Controlled Trials as Topic Severity of Illness Index Statistics for Life Sciences Study Protocol Time Factors Tomography Treatment Outcome Type 2 diabetes United Kingdom United Kingdom Cerebral glucose metabolic rate Alzheimer’s disease Liraglutide Randomised controlled trial Dementia
ISSN:	1745-6215, 1745-6215
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!